Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of dornase alpha and cisplatin in refractory germ cell cancer
2023-510135-10-00Phase 2Authorised
- Sponsor
- Národný onkologický ústav
- Start
- Jul 2025
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dornase alfa and cisplatin in germ cell tumor (GCT) and refractory germ cell tumor (RGCT), sponsored by Národný onkologický ústav. Primary endpoint: 12-week progression-free survival (PFS). Planned start Jul 2025; status: authorised.
02
Drugs
dornase alfacisplatin
03
Conditions
germ cell tumor (GCT)refractory germ cell tumor (RGCT)
Beyond the preview
Go deeper on 2023-510135-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510135-10-00.